Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen has acquired privately-held Brazilian pharmaceutical company Bergamo, an oncology medicines supplier to the hospital sector, for $215m, as part of a wider international expansion strategy.
Subscribe to our email newsletter
Amgen has also agreed to reacquire rights in Brazil to its products that were previously granted to Mantecorp (subsequently acquired by Hypermarcas).
Amgen has entered into an agreement in principle with Hypermarcas to reacquire the rights to several of Amgen’s medicines, two of which are already approved in Brazil, Vectibix (panitumumab) and Mimpara (cinacalcet).
The third medicine romiplostim (registered as Nplate in the US) is a treatment for the blood disorder ITP and is currently under review by ANVISA, the regulatory authority in Brazil.
Amgen chairman and CEO Kevin Sharer said acquiring Bergamo, a profitable company with an established local infrastructure, and regaining the rights to their products in Brazil, provides them an attractive entry into the Brazilian market.